Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos
Dimitrios H
DH
Tzakos
Andreas
A
Zografos
George
G
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A